Our pipeline consists of highly differentiated molecules that were designed and optimized to effectively block key oncogenic pathways in hematological malignancies and solid tumors to address important unmet needs in patients with cancer.
We have developed a diverse pipeline consisting of four distinct programs that utilized three unique small molecule modalities, enzyme inhibition, disruption of protein-protein interactions, and targeted protein degradation.
Our differentiation strategy is to design and optimize each of our small molecule therapeutics to possess specific properties that have the potential to benefit patients:
- PRT3789 (SMARCA2), we sought high selectivity over SMARCA4 to elicit synthetic lethality using a targeted protein degrader approach
- For PRT2527 (CDK9), we optimized for superior selectivity over previously developed CDK9i to improve tolerability
Program | Cancer Indications | Discovery | Phase 1 | Phase 2/3 | Strategic Priorities |
---|---|---|---|---|---|
PR-01 | |||||
SMARCA2 PRT3789 (IV) |
Patients with SMARCA4 mutated NSCLC and other cancers | Drive to POC in 2024 | |||
CDK9 PRT2527 |
Patients with B, T-cell malignancies and AML | Drive to POC in 2024 | |||
SMARCA2 (Oral) |
Patients with SMARCA4 mutated NSCLC and other cancers | Target IND 1H 2024 | |||
SMARCA* Precision ADC |
Solid Tumors & Heme Malignancies not addressed by selective SMARCA2 degraders | Advance a Precision ADC Program with SMARCA Payload | |||
New precision ADCs* | Solid Tumors Heme Malignancies | Continue to build Precision ADC platform with novel payloads | |||
Small Molecule Discovery | Solid Tumors Heme Malignancies | Advance a first-in-class small molecule program for a biomarker selected cancer |
PR-01 | SMARCA2 PRT3789 (IV) | |
Patients with SMARCA4 mutated NSCLC and other cancers | ||
Discovery Phase 1 Phase 2 | ||
Areas of Focus: Drive to POC in 2024 | ||
CDK9 PRT2527 | ||
Patients with B, T-cell malignancies and AML | ||
Discovery Phase 1 Phase 2 | ||
Areas of Focus: Drive to POC in 2024 | ||
SMARCA2 (Oral) | ||
Patients with SMARCA4 mutated NSCLC and other cancers | ||
Discovery Phase 1 Phase 2 | ||
Areas of Focus: Target IND 1H 2024 | ||
SMARCA* Precision ADC | ||
Solid Tumors & Heme Malignancies not addressed by selective SMARCA2 degraders | ||
Discovery Phase 1 Phase 2 | ||
Areas of Focus: Advance a Precision ADC Program with SMARCA Payload | ||
New precision ADCs* | ||
Solid Tumors Heme Malignancies | ||
Discovery Phase 1 Phase 2 | ||
Areas of Focus: Continue to build Precision ADC platform with novel payloads | ||
Small Molecule Discovery | ||
Solid Tumors Heme Malignancies | ||
Discovery Phase 1 Phase 2 | ||
Areas of Focus: Advance a first-in-class small molecule program for a biomarker selected cancer | ||
*In partnership with